serplulimab
fosun pharmaceuticals
['lcsm,(-blcsm)', 'serplulimab', 'sclc']
is there role of another anti-pd1 in es-sclc?
results from serplulimab + chemo improved os and pfs safety, as expected with addition of io
while results look good, not sure how this will fit in our current portfolio - unless there is a cost advantage #lcsm #asco22 
Leslye M. Heisler Associate Professor of Lung Cancer Excellence @PennMedicine | Faculty @PC31 | Associate Director @PennPrecisMed | Tweets my own